Pluri (NASDAQ:PLUR) Trading Up 4.7%
Pluri (NASDAQ:PLUR) Trading Up 4.7%
Shares of Pluri Inc. (NASDAQ:PLUR – Get Rating) were up 4.7% during trading on Thursday . The company traded as high as $0.92 and last traded at $0.91. Approximately 111,089 shares were traded during trading, a decline of 76% from the average daily volume of 457,724 shares. The stock had previously closed at $0.87.
在周四的交易中,Pluri Inc.(纳斯达克代码:PLUR-GET)的股价上涨了4.7%。该公司股价一度高达0.92美元,最新报0.91美元。当日成交量约为111,089股,较457,724股的日均成交量下降76%。该股此前收盘价为0.87美元。
Pluri Trading Up 2.2 %
Pluri股价上涨2.2%
The company has a current ratio of 9.91, a quick ratio of 9.91 and a debt-to-equity ratio of 0.77. The business's fifty day moving average is $0.77.
该公司的流动比率为9.91,速动比率为9.91,债务权益比率为0.77。该业务的50日移动均线切入位为0.77美元。
Institutional Trading of Pluri
普鲁里的机构交易
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PLUR. Renaissance Technologies LLC purchased a new stake in Pluri during the third quarter valued at approximately $81,000. Green Alpha Advisors LLC purchased a new stake in shares of Pluri in the third quarter worth $44,000. Values First Advisors Inc. purchased a new stake in shares of Pluri in the third quarter worth $38,000. Finally, Jane Street Group LLC purchased a new stake in shares of Pluri in the third quarter worth $28,000. 8.75% of the stock is owned by hedge funds and other institutional investors.
一些对冲基金和其他机构投资者最近增持或减持了PLUR的股份。复兴技术有限责任公司在第三季度购买了Pluri的新股份,价值约81,000美元。Green Alpha Advisors LLC在第三季度购买了价值44,000美元的Pluri新股。Values First Advisors Inc.在第三季度购买了价值3.8万美元的Pluri新股。最后,简街集团在第三季度购买了价值2.8万美元的Pluri新股。8.75%的股票由对冲基金和其他机构投资者持有。
About Pluri
关于Pluri
Pluri Inc, a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the muscle recovery following surgery for hip fracture; and Phase I/II clinical trial for the treatment of steroid-refractory graft versus host disease in collaboration with Tel Aviv Sourasky Medical Center, as well as completed a Phase II clinical trial for the treatment of acute respiratory distress syndrome associated with COVID-19 and a Phase I clinical trial for incomplete recovery following bone marrow transplantation.
Pluri Inc.是一家生物技术公司,专注于开发基于胎盘的细胞治疗产品,用于治疗炎症、肌肉损伤和血液疾病。该公司开发以胎盘扩大(PLX)为基础的细胞治疗产品,包括针对髋部骨折手术后肌肉恢复的PLX-PAD处于第三阶段临床试验;与特拉维夫Sourasky医学中心合作治疗激素难治性移植物抗宿主疾病的I/II阶段临床试验;以及治疗与新冠肺炎相关的急性呼吸窘迫综合征的第二阶段临床试验和骨髓移植后不完全恢复的第一阶段临床试验。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Pluri (PLUR)
- MarketBeat: Week in Review 12/05 – 12/09
- There Is Fundamental Value In Broadcom, And It Yields 3.35%
- Costco vs Amazon: an end of the year showdown
- Discount Retailers Could Make Good Bargain Stocks
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
- 免费获取StockNews.com关于Pluri的研究报告(PLUR)
- MarketBeat:回顾一周12/05-12/09
- 博通有基本面价值,收益率为3.35%
- 好市多VS亚马逊:年底摊牌
- 折扣零售商可以做好的便宜货
- 辉瑞、强生能否继续跑赢该指数?
Receive News & Ratings for Pluri Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluri and related companies with MarketBeat.com's FREE daily email newsletter.
接受Pluri Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Pluri和相关公司的最新新闻和分析师评级的每日简要摘要。